NCT01818544 - Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Bronchiectasis

Interventions

DRUG

BAY85-8501

BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning

DRUG

Placebo

Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning

Trial Locations (33)

10043

Orbassano

15562

Rüdersdorf

16132

Genova

17190

Salt

20142

Milan

20354

Hamburg

22927

Großhansdorf

23538

Lübeck

24105

Kiel

28046

Madrid

28222

Majadahonda

30167

Hanover

35128

Padua

53100

Siena

66025

Perpignan

80131

Napoli

93093

Donaustauf

06000

Nice

04103

Leipzig

07740

Jena

08916

Badalona

SO16 6YD

Southampton

HU16 5JQ

Cottingham

LE3 9QP

Leicester

L9 7JU

Liverpool

S5 7AU

Sheffield

DD2 1UB

Dundee

NE7 7DN

Newcastle upon Tyne

NE34 0PL

South Shields

WV10 0QP

Wolverhampton

BD9 6RJ

Bradford

G42 9TY

Glasgow

EC1M 6BQ

London